CCRS/△ccr5 heterozygosity:: A selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype

被引:28
作者
D'Aquila, RT
Sutton, L
Savara, A
Hughes, MD
Johnson, VA
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[3] London Sch Hyg & Trop Med, London WC1, England
[4] Univ Alabama, Sch Med, Birmingham, AL USA
[5] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA
关键词
D O I
10.1086/515307
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mechanisms underlying the delay in dominance of syncytium-inducing (SI) phenotype HIV-1 (human immunodeficiency virus type 1) in vivo are unknown. Both random mutational events and selective pressures operative only late in the disease process have been suggested to underlie the shift from CCR5 to alternative coreceptor usage, Among the moderately advanced patients who entered AIDS Clinical Trials Group protocol 241, SI viral phenotype was more common among CCR5/Delta ccr5 heterozygotes (7/7, 100%) than among CCR5/CCR5 homozygotes (29/88, 33%; P < .001, Fisher's exact test). Other characteristics did not differ at study entry by CCR5 genotype, including median CD4 cell counts, plasma RNA levels, and infectious HIV-I titers in circulating cells. These data indicate that CCR5/Delta ccr5 heterozygosity, which decreases cell-surface levels of CCR5 available to serve as an HIV-1 entry coreceptor, is a selective pressure for evolution of T cell line-tropic viruses that use an alternative coreceptor.
引用
收藏
页码:1549 / 1553
页数:5
相关论文
共 35 条
[1]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[2]   HIV blocked by chemokine antagonist [J].
ArenzanaSeisdedos, F ;
Virelizier, JL ;
Rousset, D ;
ClarkLewis, I ;
Loetscher, P ;
Moser, B ;
Baggiolini, M .
NATURE, 1996, 383 (6599) :400-400
[3]   The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J].
Bleul, CC ;
Farzan, M ;
Choe, H ;
Parolin, C ;
ClarkLewis, I ;
Sodroski, J ;
Springer, TA .
NATURE, 1996, 382 (6594) :829-833
[4]   A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) [J].
Bleul, CC ;
Fuhlbrigge, RC ;
Casasnovas, JM ;
Aiuti, A ;
Springer, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1101-1109
[5]   A CROSS-SECTIONAL COMPARISON OF PERSONS WITH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BOZZETTE, SA ;
MCCUTCHAN, JA ;
SPECTOR, SA ;
WRIGHT, B ;
RICHMAN, DD .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1374-1379
[6]   HIV-1: Gambling on the evolution of drug resistance? [J].
Brown, AJL ;
Richman, DD .
NATURE MEDICINE, 1997, 3 (03) :268-271
[7]   Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4(+) T cells [J].
Carroll, RG ;
Riley, JL ;
Levine, BL ;
Feng, Y ;
Kaushal, S ;
Ritchey, DW ;
Bernstein, W ;
Weislow, OS ;
Brown, CR ;
Berger, EA ;
June, CH ;
StLouis, DC .
SCIENCE, 1997, 276 (5310) :273-276
[8]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[9]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628
[10]   Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - A randomized, double-blind, placebo-controlled trial [J].
DAquila, RT ;
Hughes, MD ;
Johnson, VA ;
Fischl, MA ;
Sommadossi, JP ;
Liou, SH ;
Timpone, J ;
Myers, M ;
Basgoz, N ;
Niu, M ;
Hirsch, MS ;
Costanzo, L ;
Ruben, S ;
Berzins, B ;
Martinez, A ;
Fishman, I ;
Kazial, K ;
Cort, SN ;
Robinson, P ;
Hall, D ;
Macy, H ;
McLaren, C ;
Rooney, J ;
Warwick, J ;
CavailleColl, M ;
Valentine, F ;
Booth, D ;
Soeiro, R ;
Stein, D ;
Zingman, B ;
Schliosberg, J ;
Polsky, B ;
Sepkowitz, K ;
Sharpe, V ;
Giordano, M ;
Wanke, C ;
Gulick, R ;
Craven, D ;
Grodman, C ;
Fife, K ;
Black, J ;
Todd, K ;
Nixon, H ;
Sperber, K ;
Gerits, P ;
Mildvan, D ;
Nicholas, P ;
Murphy, RL ;
Kessler, H ;
Pulvirenti, J .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1019-1030